Subscribe to RSS
DOI: 10.1055/s-2002-31523
Psychopharmacological Treatment of Aggression
in Schizophrenic Patients
Publication History
Publication Date:
23 May 2002 (online)
![](https://www.thieme-connect.de/media/pharmaco/200203/lookinside/thumbnails/10.1055-s-2002-31523-1.jpg)
Aggressive behavior is frequently observed in schizophrenic patients. More than 50 % of all psychiatric patients and 10 % of schizophrenic patients show aggressive symptoms varying from threatening behavior and agitation to assault. The pharmacological treatment of acute, persisting and repetitive aggression is a serious problem for other patients and staff members. Not only is violent behavior from mentally ill patients the most detrimental factor in their stigmatization, aggression is also a considerable direct source of danger for the patients themselves.
Based on rather limited evidence, a wide variety of medications for the pharmacological treatment of aggression has been recommended: typical and atypical antipsychotics, benzodiazepines, mood stabilizers, beta-blockers and selective serotonin reuptake inhibitors (SSRIs).
Most clinical information on treating aggression has been collected for atypical neuroleptics, particularly for clozapine. Several retrospective and open studies indicate its efficacy. Treatment duration of 6 months is recommended to induce a stable reduction of physical and verbal aggression. Severe side effects have very rarely been seen. At the moment, clozapine seems to be the first choice in aggression treatment. Within the last few years, about 10 articles were published showing that this is the most effective antiaggressive agent in the treatment of aggression and agitation in psychiatric patients, independent of psychiatric diagnosis. However, clozapine, like all the other substances used, does not have an established indication for the treatment of aggressive symptoms. Noncompliance with medication makes it difficult to choose the right preparation for the medication: tablets, liquids, intramuscular injections and readily soluble “FDDFs” are available. Ethical, juridical and methodological problems prevent controlled studies from establishing a reference in the treatment of aggression in mentally ill patients. This review summarizes the current discussion and publications on the pharmacological treatment of aggression in schizophrenic patients of the last 20 years. In addition, we will briefly present studies and case reports concerning the treatment of aggression in other psychiatric patients.
References
- 1 Bienik S A, Ownby R L, Penalver A, Dominguez R A. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 1998; 18 57-62
-
2 Brecher M, Clyde C, Group T RS.
Risperidone in the treatment of psychosis and aggressive behavior in patients. In: Las Croabas Puerto Rico; The American College of Neuropsychopharmacology 1998 - 3 Buckley P F. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psych. 1999; 60 (10) 52-60
- 4 Buckley P F, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz S C. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psych Law. 1995; 23 607-611
- 5 Buckley P F, Ibrahim Z Y, Singer B, Orr B, Donenwirth K, Brar P S. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psych Law. 1997; 25 173-181
- 6 Cabrera J F, Körner W, Müller-Oerlinghausen B. Erfolgreiche kombinierte Neuroleptika-Lithium-Behandlung eines chronisch schizophrenen Kranken mit rezidivierendem aggressivem Verhalten. Nervenarzt. 1986; 57 366-369
- 7 Campbell M, Cohen I L, Small A M. Drugs in aggressive behavior. J Am Acad Child Psychiatry. 1982; 21 107-117
- 8 Campbell M, Small A M, Green W H, Jennings S J, Perry R, Bennet W G, Andersson L. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorders. Arch Gen Psychiat. 1984a; 41 650-656
- 9 Campbell M, Perry R, Green W H. Use of lithium in children and adolescents. Psychosomatics. 1984b; 25 95-106
- 10 Campbell M, Adams P B, Small A M, Kafantaris V, Silva R R, Shell J, Overall J E. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1995; 34 445-453
- 11 Chiles J A, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint in a state hospital. Hosp Comm Psych. 1994; 45 269-271
- 12 Corrigan P W, Yudolfsky S C, Silver J M. Pharmacological and behavioral treatments for aggressive psychiatric inpatients. Hosp Comm Psych. 1993; 44 125-133
- 13 Curtis J L. Psychotropic medication use in people with developmental disabilities. Md Med J. 1997; 46 481-485
- 14 Czobor P, Volavka J, Meibach R C. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995; 15 243-249
- 15 Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular Flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry. 1999; 156 142-144
- 16 Dubin W R. Rapid tranquillisation: antipsychotics or benzodiazepines?. J Clin Psych. 1988; 49 (12) 5-12
- 17 Ebrahim G M, Gibler B, Gacono G B. Patient response to clozapine in a forensic psychiatric hospital. Hosp Comm Psych. 1994; 45 271-273
- 18 Eimer M. Management of the behavioral symptoms associated with dementia. Prim Care. 1989; 16 431-450
- 19 Elphick M. Clinical issues ina the use of carbamazepine in psychiatry: a review. Psychol Med. 1989; 19 591-604
- 20 Fava M. Psychopharmacologic treatment of pathologic aggression. Psych Clin North Am. 1997; 20 427-451
- 21 Fritze J, Beneke M, Lanczik M, Schneider B, Walden J. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders. Pharmacopsychiat. 1994; 27 181-185
- 22 Garmendia L, Sanchez J R, Azpiroz A, Brain P F, Simon V M. Clozapine: strong antiaggressive effects with minimal motor impairment. Physiol Behav. 1991; 51 51-54
- 23 Glazer W M, Dickson R A. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psych. 1998; 59 (3) 8-14
- 24 Goldberg R J, Dubin W R, Fogel B S. Review: Behavioral emergencies, assessment of psychopharmacologic management. Clin Neuropharm. 1989; 12 233-248
- 25 Greendyke R M, Kanter D R, Schuster D B, Verstreate S, Wootton J. Propanolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. J Nerv Ment Dis. 1986; 174 290-294
- 26 Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy. 1998; 18 600-606
- 27 Hector R I. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psych. 1998; 43 466-472
- 28 Laurijssens B E, Greenblatt D J. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokin. 1996; 30 52-76
-
29 Laux G, Dietmeier O, König W.
Psychopharmaka - ein Leitfaden. 5. Aufl. Ulm, Stuttgart, Jena, New York; Fischer 1995 - 30 Lemke M R, Stuhlmann W. Therapeutische Anwendung von Carbamazepin bei Antriebssteigerung und Affektstörungen gerontopsychiatrischer Patienten. Psychiatrische Praxis. 1994; 21 147-150
- 31 Lenox R H, Newhouse P A, Creelman W L, Whitacker T M. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psych. 1992; 53 47-52
- 32 Luchins D J. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacology Bulletin. 1984; 20 (3) 569-571
- 33 Mallya A R, Roos P D, Roebuck-Colgan K. Restraint, seclusion, and clozapine. J Clin Psych. 1992; 53 395-397
- 34 Marder S R, Davis J M, Chouinard G. The effects of rsiperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trial. Jour Clin Psych. 1997; 58 (12) 538-546
- 35 Markovitz P J, Calabrese J R, Schulz S C, Meltzer H Y. Fluoxetine in the treatment of borderline and schizotypal personality disorder. Am J Psych. 1991; 148 1064-1067
- 36 Mattes J A. Carbamazepine vs. propanolol for rage outbursts. Psychopharmacol Bull. 1988; 24 179-182
- 37 McDougle C J, Homes J P, Carlson D C. A double-blind placebo controlled study of rsiperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psych. 1998; 55 633-641
- 38 McDouble C J, Naylor S T, Cohen D J, Volkmar F R, Heninger G R, Price L H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996; 53 1001-1008
- 39 Morrison E F. A hierachy of aggressive and violent behaviors among psychiatric inpatients. Hosp Comm Psych. 1992; 43 505-506
-
40 Nilsson A.
Lithium in der Therapie und Prophylaxe pathologischer Aggression. In: Müller-Oerlinghausen B (ed) Die Lithiumtherapie: Nutzen, Risiken, Alternativen. Berlin; Springer 1997: 278-289 -
41 Nissen G, Fritze J, Trott G E.
Psychopharmaka im Kindes- und Jugendalter. Ulm, Stuttgart, Jena, Lübeck; Fischer 1998 - 42 Okuma T, Yamashita I, Takahashi R. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatr Scand. 1989; 80 250-259
- 43 Pabis D J, Stanislaw S W. Pharmacotherapy of aggressive behavior. Ann Pharmacother. 1996; 30 278-287
- 44 Pilowsky L S, Ring H, Shine P J, Battersby M, Lader M. Rapid tranquillisation - a survey of emergency prescribing in a general psychiatric hospital. Br J Psych. 1992; 160 831-835
- 45 Polakoff S A, Sorgi P J, Ratey J J. The treatment of impulsive and aggressive behavior with nadolol. J Clin Psychopharmacol. 1996; 6 125-126
- 46 Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996; 22 249-255
- 47 Ratey J J, Leveroni C, Kilmer D. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psych. 1993; 54 219-223
- 48 Rittmannsberger H. Carbamazepin in der Behandlung psychischer Erkrankungen: Wirkungen und Nebenwirkungen. Wiener Med Woch. 1990; 15 398-404
- 49 Ruedrich S L, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive and self-injurious mentally retarded persons. Am J Mental Retard. 1990; 95 110-119
- 50 Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychiatric disorder behavior. J Clin Psych. 1991; 52 177-180
- 51 Schneider L S, Sobin P B. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharm Bull. 1992; 28 71-79
- 52 Sheppard G P. High-dose propanolol in schizophrenia. Br J Psych. 1979; 134 470-476
- 53 Silver H, Kushnir M. Treatment of aggression in schizophrenia. Br J Psych. 1998; 155 1298
- 54 Sorgi P J, Ratey J J, Polakoff S. Beta-adrenergic blockers for the control of aggressive behavior in patients with chronic schizophrenia. Am J Psych. 1986; 143 775-776
- 55 Stanislaw S. Neuere Tendenzen in der Pharmakotherapie aggressiven Verhaltens bei psychisch Kranken. Fortschr Neurol Psychiatr. 1992; 60 393-400
- 56 Steinert T. Neuere Tendenzen in der Pharmakotherapie aggressiven Verhaltens bei psychisch Kranken. Fortschr Neurol Psychiatr. 1992; 60 393-400
- 57 Steinert T, Sippach T, Gebhardt R P. How common is violence in schizophrenia despite neuroleptic treatment?. Pharmacopsych. 2000; 33 98-102
- 58 Swanson J, Holzer C, Ganju V. volence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment area surveys. Hosp Comm Psych. 1990; 41 761-770
- 59 Tauscher J, Kasper S. Sertralin - selektiver Serotonin-Wiederaufnahmehemmer mit geringem Interaktionsprofil. Fundamenta Psychiatrica. 1997; 11 179-189
-
60 Taylor P J.
Schizophrenia and crime: distinctive patterns in association. In: Hodgins S (ed) Crime and mental disorder. Newbury Park, CA USA; Sage Publications 1993 - 61 Tyrer S P, Walsh A, Edwards D E, Berney T P, Stephens D A. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Prog Neuropsychopharmacol. 1984; 8 751-755
- 62 Vartiainen H, Tiihonen J, Putkonen A, Koponen H, Virkkkunen M, Hakola P. Citalopram, a selective serotinin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scan. 1995; 91 348-351
- 63 Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psych. 1999; 60 (12) 43-46
-
64 Volavka J.
The neurobiology of violence. Washington DC, USA; Am Psych Press 1995 - 65 Volavka J, Citrome L. Atypical antipsychotics in the treatment of persistently aggressive psychotic patients: methodological concerns. Schizophrenia Res. 199; 35 S23-S33
- 66 Volavka J, Zito J M, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol. 1993; 13 287-289
- 67 Weiden P J, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995; 21 419-429
- 68 Wessely S. the epidemiology of crime, violence and schizophrenia. Br J Psych. 1997; 170 (32) 8-11
- 69 Wilson W H. Clinical review of clozapine treatment in a state hospital. Hosp comm Psych. 1992; 43 700-703
- 70 Wroblewski B A, Joseph A B, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired head injury. Brain Inj. 1997; 11 37-47
- 71 Yudofsky S C, Silver J M, Jackson W, Endicott J, Williams D. The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986; 143 35-39
- 72 Yudofsky S C, Silver J M, Hales R E. Pharmacologic management of aggression in the elderly. J Clin Psych. 1990; 51 (10) 22-28
Prof. Dr. med. Dieter Naber
Department of Psychiatry and Psychotherapy, University Hospital Eppendorf
Martinistraße 52
20246 Hamburg
Germany
Phone: + 49-40-42803-2231
Fax: + 49-40-42803-9135